The physician survey aims to understand the context of the real-world clinical setting and shed light on the utilization of FDC treatments by the prescribing physicians. The retrospective patient chart review will gain insights in real-world data of the patient's characteristics with a treatment decision for the FDC. No study drugs will be provided or administered as part of this protocol.~The objectives of the physician survey are the evaluation of the key factors for the therapy decision for the FDC:~LDL-C levels at therapy decision and goal of LDL-C reduction~Relevance of different factors and considerations~Considerations of guidelines~The objectives of the retrospective patient chart review are to characterize the patients':~Demographics~LDL-C levels at therapy decisions~Medical History~Concomitant Diseases~Lifestyle Modifications
In this study, a survey of office-based cardiologists and lipid management specialists will be conducted on treatment decisions for NUSTENDI® (bempedoic acid 180 mg fixed dose combination [FDC] with ezetimibe 10 mg) followed by a retrospective chart review of patients at high and very-high cardiovascular risk with hypercholesterolemia or mixed dyslipidemia who were treated with FDC as add-on to treatment with maximally tolerated statin therapy in routine clinical practice.